Research into pancreatic cancer is advancing thanks to the insights gained from the THERGAP-2 clinical trial. For two decades, teams from CHU Toulouse, Inserm, and the biotechnology company InvivoGen collaborated on this gene therapy approach.
Although the trial did not demonstrate enhanced chemotherapy efficacy, it validated the feasibility of directly injecting the gene therapy product into the tumor. This procedure was successfully performed in seven French hospital centers across patients of various ages.
The study also contributed to a better understanding of the treatment's effects, through complementary analyses conducted by Inserm teams. The ongoing collaboration between medical teams, researchers, and the biotechnology company is deemed crucial for advancing research in this field.
“"The knowledge gained from this trial will allow us to better guide our research and explore new avenues to ultimately improve the management of pancreatic cancer."
The full study is accessible online.
